Form 4: Karyopharm Therapeutics CEO Richard Paulson Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Karyopharm Therapeutics CEO Richard Paulson sold 3,573 shares of common stock on March 5, 2024, to cover withholding tax liabilities.
Summary
- Richard A. Paulson, CEO of Karyopharm Therapeutics Inc., sold 3,573 shares of common stock on March 5, 2024.
- The sale was executed at a weighted average price of $1.3 per share, with individual transactions ranging from $1.28 to $1.30.
- The transaction was conducted under a pre-arranged automatic sale plan adopted on June 10, 2021, to cover withholding tax obligations arising from the vesting of restricted stock units.
- Following the sale, Paulson directly owns 1,160,836 shares of Karyopharm Therapeutics Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The sale is related to tax obligations and doesn't necessarily reflect a negative view of the company's future. The CEO still holds a significant number of shares.
Industry Context
Insider sales are a common occurrence, and this transaction appears to be related to tax obligations rather than a change in sentiment regarding the company's prospects. Investors often monitor insider transactions for signals about a company's health and future performance.
Stakeholder Impact
- The sale of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to have a significant long-term effect given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| 2021-06-10 | Date of adoption of the durable automatic sale instruction plan. |
| 2024-03-05 | Date of the stock sale transaction. |
| 2024-03-06 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.